The SP weakness is purely a transitory biopharma beta move and...

The SP weakness is purely a transitory biopharma beta move and not to be worried about. Trump will have no adverse impact on SRX in spite of the following from XinHua, in fact, the overstated political implications of Trump for SRX r a small buying opportunity until FOMO regains its ground.
"Health Care subgroup was hit hard, as United States president-elect Donald Trump stated that he would lower drug prices in his interview with Time magazine after being named their 'Person of the Year' . As a result, Quebec-based drugmakers ProMetic Life Sciences and Valeant Pharmaceuticals International Inc. tumbled 4.59 percent and 3.76 percent, respectively."
http://news.xinhuanet.com/english/2016-12/08/c_135888746.htm